Human Genome Sciences

hgsi.com

Human Genome Sciences (HGS) is a biopharmaceutical company with world-class R&D and manufacturing facilities and a newly created commercial team based in Rockville, MD. We have recently received approval for our first commercial product; and currently have several other products in the pipeline undergoing clinical trials.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

news image

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

news image

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

news image

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More

MedTech

STEVANATO GROUP LAUNCHES EZ-FILL® KIT AND LABORATORY FILL AND FINISH SERVICE TO SUPPORT SMALL BATCH DRUG DEVELOPMENT AND COMMERCIALIZATION

Stevanato Group | January 25, 2024

news image

Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group’s new EZ-fill® Kit offers fast access to ...

Read More
news image

Industrial Impact, Medical

HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO DEVELOP IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR SYNDROME PATIENTS

prnewswire | April 28, 2023

Hansa Biopharma AB, "Hansa" a pioneer in enzyme technology for rare immunological conditions, and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, announced they have entered a research and development collaboration. The collaboration will, in a clinical study, evaluate the safety and efficacy of Hansa's antibody cleaving enzyme imlifidase as a pre-treatment prior to the administration of Genethon's gene thera...

Read More
news image

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More
news image

UNUM THERAPEUTICS ANNOUNCED THE TRANSFER OF BOXR CELL-BASED THERAPY TECHNOLOGY TO SOTIO

Cision PR Newswire | August 31, 2020

Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sale of its cell-based BOXR programs to SOTIO, a clinical stage immuno-oncology company owned by PPF Group. Under the terms of the agreement, SOTIO will make an upfront payment of $8.1 million for the BOXR technology and will assume development of Unum's lead cand...

Read More
news image

MedTech

STEVANATO GROUP LAUNCHES EZ-FILL® KIT AND LABORATORY FILL AND FINISH SERVICE TO SUPPORT SMALL BATCH DRUG DEVELOPMENT AND COMMERCIALIZATION

Stevanato Group | January 25, 2024

Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, unveiled today two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers (TEC). In a context where reducing time-to-market is key, Stevanato Group’s new EZ-fill® Kit offers fast access to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us